PRQR
ProQR Therapeutics N.V.
Price Chart
Latest Quote
$1.89
+0.22 (+13.17%)
Current Price
| Previous Close | $1.67 |
| Open | $1.67 |
| Day High | $1.97 |
| Day Low | $1.67 |
| Volume | 1,378,074 |
Stock Information
Note: Financial values converted from EUR to USD
| Shares Outstanding | 105.36M |
| Total Debt | $18.01M |
| Cash Equivalents | $92.83M |
| Revenue | $15.61M |
| Net Income | $-52.08M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $199.14M |
| EPS (TTM) | $-0.50 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $133.78M |
| Sales | $15.61M |
| Income | $-52.08M |
| Book/sh | $0.41 |
| Cash/sh | $0.77 |
| Employees | 186 |
Financial Ratios
| Quick Ratio | 2.39 |
| Current Ratio | 2.48 |
| Debt/Eq | 41.84 |
Returns & Margins
| ROA | -23.07% |
| ROE | -78.07% |
| Gross Margin | 100.00% |
| Operating Margin | -671.37% |
Ownership
| Insider Ownership | 17.66% |
| Institutional Ownership | 48.94% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.78 |
| P/S | 14.60 |
| P/B | 4.62 |
Analyst Data
| Recommendation | none |
| Target Price | $8.88 |
Technical Indicators
| SMA20 | $1.53 |
| SMA50 | $1.62 |
| SMA200 | $1.92 |
| RSI | 65.35 |
| ATR | 0.1312 |
| Shares Float | 64.35M |
| Short Float | 1.24% |
| Short Ratio | 1.61 |
| Volatility | 0.06 |
| Rel Volume | 2.37 |
Performance History
| Week | +31.25% |
| Month | +32.17% |
| Quarter | +18.87% |
| 6 Months | -16.74% |
| YTD | -5.03% |
| Year | +0.00% |
| 3 Years | +11.83% |
| 5 Years | -72.04% |
| 10 Years | -61.35% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $1.89 | 1,378,100 |
| 2026-06-17 | $1.67 | 913,300 |
| 2026-06-16 | $1.52 | 204,300 |
| 2026-06-15 | $1.56 | 719,400 |
| 2026-06-12 | $1.44 | 315,900 |
| 2026-06-11 | $1.44 | 346,100 |
| 2026-06-10 | $1.41 | 466,200 |
| 2026-06-09 | $1.47 | 476,800 |
| 2026-06-08 | $1.53 | 387,300 |
| 2026-06-05 | $1.50 | 449,700 |
| 2026-06-04 | $1.53 | 545,400 |
| 2026-06-03 | $1.47 | 661,700 |
| 2026-06-02 | $1.47 | 1,138,300 |
| 2026-06-01 | $1.42 | 784,400 |
| 2026-05-29 | $1.58 | 684,600 |
| 2026-05-28 | $1.57 | 167,700 |
| 2026-05-27 | $1.56 | 231,500 |
| 2026-05-26 | $1.57 | 440,600 |
| 2026-05-22 | $1.56 | 551,600 |
| 2026-05-21 | $1.44 | 777,400 |
| 2026-05-20 | $1.43 | 1,254,200 |
| 2026-05-19 | $1.43 | 414,900 |
About ProQR Therapeutics N.V.
ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs. Its lead product candidate, AX-0810, targets na-taurocholate cotransporting polypeptide (NTCP) for the treatment of cholestatic diseases. The company also develops AX-2402, which targets methyl CpG binding protein 2 mutations for Rett syndrome; AX-2911, which targets PNPLA3 for metabolic dysfunction-associated steatohepatitis; and AX-1412, which targets the B4GALT1 gene for cardiovascular diseases. It has a research and collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
đ° Latest News
Undervalued Penny Stocks To Consider In June 2026
Simply Wall St. âĸ 2026-06-08T12:05:05Z
ProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%
Simply Wall St. âĸ 2026-05-14T12:25:53Z
Kamada (KMDA) Misses Q1 Earnings and Revenue Estimates
Zacks âĸ 2026-05-13T12:15:02Z
Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline
Zacks âĸ 2026-05-07T14:00:04Z
3 Promising Penny Stocks With Market Caps Up To $600M
Simply Wall St. âĸ 2026-05-06T18:05:45Z
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
Zacks âĸ 2026-04-30T21:30:05Z
ProQR Therapeutics Unveils New RNA Editing Programs; AX-0810 Phase 1 Target Data Due This Quarter
MarketBeat âĸ 2026-04-08T16:05:29Z
April 2026 Penny Stock Highlights
Simply Wall St. âĸ 2026-04-03T18:05:10Z
Oppenheimer Predicts Up to ~560% Rally for These 2 âStrong Buyâ Stocks
TipRanks âĸ 2026-03-29T10:15:00Z
Growing Optimism About ProQR Therapeutics (PRQR)âs RNA Editing Platform and Future Clinical Catalysts
Insider Monkey âĸ 2026-03-25T19:29:34Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $18,242,916 | $21,682,530 | $7,471,039 | $4,122,032 |
| Operating Revenue | $18,242,916 | $21,682,530 | $7,471,039 | $4,122,032 |
| Expenses | ||||
| Interest Expense | $1,065,489 | $1,235,233 | $1,379,745 | $5,880,261 |
| Total Expenses | $68,072,020 | $56,631,489 | $47,372,400 | $78,854,218 |
| Other Income Expense | $-141,071 | $387,659 | $6,407,844 | $6,964,101 |
| Other Non Operating Income Expenses | $269,526 | $395,688 | $1,093,015 | $3,111,595 |
| Net Non Operating Interest Income Expense | $1,610,276 | $2,493,405 | $1,594,219 | $-5,758,687 |
| Interest Expense Non Operating | $1,065,489 | $1,235,233 | $1,379,745 | $5,880,261 |
| Operating Expense | $68,072,020 | $56,631,489 | $47,372,400 | $78,854,218 |
| Other Operating Expenses | $-505,792 | $-734,029 | $-91,754 | $-877,394 |
| General And Administrative Expense | $17,272,621 | $15,668,080 | $18,621,400 | $21,391,212 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-48,381,690 | $-31,841,951 | $-32,250,255 | $-73,889,200 |
| Net Interest Income | $1,610,276 | $2,493,405 | $1,594,219 | $-5,758,687 |
| Interest Income | $2,675,765 | $3,728,638 | $2,973,965 | $121,574 |
| Normalized Income | $-48,057,318 | $-31,833,979 | $-37,549,139 | $-76,939,928 |
| Net Income From Continuing And Discontinued Operation | $-48,381,690 | $-31,841,951 | $-32,250,255 | $-73,889,200 |
| Total Operating Income As Reported | $-49,829,104 | $-34,948,958 | $-36,539,737 | $-74,732,186 |
| Net Income Common Stockholders | $-48,381,690 | $-31,841,951 | $-32,250,255 | $-73,889,200 |
| Net Income | $-48,381,690 | $-31,841,951 | $-32,250,255 | $-73,889,200 |
| Net Income Including Noncontrolling Interests | $-48,381,690 | $-31,841,951 | $-31,809,837 | $-73,636,877 |
| Net Income Continuous Operations | $-48,381,690 | $-31,841,951 | $-31,809,837 | $-73,636,877 |
| Pretax Income | $-48,359,899 | $-32,067,894 | $-31,899,297 | $-73,526,773 |
| Special Income Charges | $0 | $0 | $5,607,294 | $-1,594,219 |
| Interest Income Non Operating | $2,675,765 | $3,728,638 | $2,973,965 | $121,574 |
| Operating Income | $-49,829,104 | $-34,948,958 | $-39,901,361 | $-74,732,186 |
| Earnings From Equity Interest | - | $0 | $0 | $-9,175 |
| Per Share | ||||
| Diluted EPS | $-0.46 | $-0.37 | $-0.40 | $-1.03 |
| Basic EPS | $-0.46 | $-0.37 | $-0.40 | $-1.03 |
| Other | ||||
| Tax Effect Of Unusual Items | $-86,225 | $-56 | $15,944 | $810,953 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-43,783,686 | $-27,657,985 | $-32,952,170 | $-68,616,807 |
| Total Unusual Items | $-410,598 | $-8,028 | $5,314,829 | $3,861,681 |
| Total Unusual Items Excluding Goodwill | $-410,598 | $-8,028 | $5,314,829 | $3,861,681 |
| Reconciled Depreciation | $3,100,126 | $3,166,647 | $2,882,211 | $2,891,386 |
| EBITDA (Bullshit earnings) | $-44,194,284 | $-27,666,014 | $-27,637,341 | $-64,755,126 |
| EBIT | $-47,294,410 | $-30,832,661 | $-30,519,552 | $-67,646,512 |
| Diluted Average Shares | $120,810,123 | $98,734,347 | $92,913,671 | $82,166,874 |
| Basic Average Shares | $120,810,123 | $98,734,347 | $92,913,671 | $82,166,874 |
| Diluted NI Availto Com Stockholders | $-48,381,690 | $-31,841,951 | $-32,250,255 | $-73,889,200 |
| Minority Interests | $0 | $0 | $-440,417 | $-252,322 |
| Tax Provision | $21,791 | $-225,943 | $-89,460 | $110,104 |
| Gain On Sale Of Ppe | $0 | $0 | $3,361,624 | $0 |
| Gain On Sale Of Business | $0 | $0 | $105,517 | $0 |
| Gain On Sale Of Security | $-410,598 | $-8,028 | $-292,465 | $5,455,900 |
| Research And Development | $51,305,190 | $41,697,438 | $28,842,754 | $58,340,400 |
| Selling General And Administration | $17,272,621 | $15,668,080 | $18,621,400 | $21,391,212 |
| Other Gand A | $17,272,621 | $15,668,080 | $18,621,400 | $21,391,212 |
| Other Special Charges | - | - | $-2,140,153 | $1,594,219 |
Fetched: 2026-06-21
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $56,628,048 | $101,571,271 | $47,471,035 | $76,918,217 |
| Total Assets | $129,322,157 | $192,634,457 | $158,140,826 | $196,491,550 |
| Total Non Current Assets | $14,485,605 | $16,186,488 | $19,379,514 | $19,338,225 |
| Investmentin Financial Assets | $0 | $0 | $0 | $712,238 |
| Current Assets | $114,836,552 | $176,447,969 | $138,761,312 | $177,153,325 |
| Prepaid Assets | $3,012,960 | $2,764,078 | $909,508 | $2,808,808 |
| Receivables | $5,833,237 | $2,324,808 | $1,454,295 | $65,645,136 |
| Other Receivables | $934,740 | $1,533,433 | $854,456 | $64,948,955 |
| Taxes Receivable | $1,047,138 | $791,375 | $599,839 | $696,181 |
| Accounts Receivable | $3,851,359 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $105,990,355 | $171,359,083 | $136,397,509 | $108,699,381 |
| Cash And Cash Equivalents | $105,990,355 | $171,359,083 | $136,397,509 | $108,699,381 |
| Cash Equivalents | $62,688,375 | $86,258,736 | $67,840,342 | $0 |
| Cash Financial | $43,301,980 | $85,100,347 | $68,557,167 | $108,699,381 |
| Debt | ||||
| Total Debt | $18,309,437 | $19,745,382 | $22,633,327 | $25,198,988 |
| Long Term Debt And Capital Lease Obligation | $10,949,649 | $12,692,968 | $20,782,198 | $20,740,909 |
| Current Debt And Capital Lease Obligation | $7,359,788 | $7,052,414 | $1,851,130 | $4,458,080 |
| Current Debt | $5,587,796 | $5,255,189 | - | $2,867,301 |
| Other Current Borrowings | $5,587,796 | $5,255,189 | - | $2,867,301 |
| Long Term Debt | - | - | $4,922,582 | $4,898,497 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $72,694,109 | $91,063,186 | $110,669,790 | $120,013,751 |
| Total Non Current Liabilities Net Minority Interest | $35,486,864 | $46,445,689 | $71,441,672 | $95,942,185 |
| Non Current Deferred Liabilities | $24,537,215 | $33,752,720 | $50,659,474 | $75,201,277 |
| Current Liabilities | $37,207,245 | $44,617,497 | $39,228,118 | $24,071,565 |
| Other Current Liabilities | $9,374,927 | $10,685,857 | $10,115,838 | $11,411,858 |
| Current Deferred Liabilities | $20,130,747 | $25,165,727 | $23,591,006 | $6,469,778 |
| Payables And Accrued Expenses | $341,782 | $1,713,499 | $3,670,145 | $1,731,850 |
| Payables | $341,782 | $1,713,499 | $3,670,145 | $1,731,850 |
| Total Tax Payable | $0 | $1,695,148 | $1,902,741 | $1,282,257 |
| Accounts Payable | $341,782 | $18,351 | $1,767,404 | $449,593 |
| Equity | ||||
| Common Stock Equity | $56,628,048 | $101,571,271 | $47,471,035 | $76,918,217 |
| Total Equity Gross Minority Interest | $56,628,048 | $101,571,271 | $47,471,035 | $76,477,799 |
| Stockholders Equity | $56,628,048 | $101,571,271 | $47,471,035 | $76,918,217 |
| Gains Losses Not Affecting Retained Earnings | $32,906,293 | $31,652,709 | $29,792,404 | $34,710,399 |
| Retained Earnings | $-536,192,169 | $-489,916,224 | $-459,743,042 | $-434,807,846 |
| Long Term Equity Investment | - | - | - | $0 |
| Other | ||||
| Treasury Shares Number | $2,695,093 | $2,865,453 | $3,318,949 | $3,933,809 |
| Ordinary Shares Number | $120,840,754 | $120,670,394 | $93,307,241 | $92,690,757 |
| Share Issued | $123,535,847 | $123,535,847 | $96,626,190 | $96,624,565 |
| Tangible Book Value | $56,628,048 | $101,571,271 | $47,471,035 | $76,918,217 |
| Invested Capital | $62,215,844 | $106,826,460 | $52,393,618 | $84,684,015 |
| Working Capital | $77,629,307 | $131,830,472 | $99,533,193 | $153,081,760 |
| Capital Lease Obligations | $12,721,641 | $14,490,192 | $17,710,745 | $17,433,190 |
| Total Capitalization | $56,628,048 | $101,571,271 | $52,393,618 | $81,816,714 |
| Minority Interest | $0 | $0 | $0 | $-440,417 |
| Additional Paid In Capital | $554,972,990 | $554,893,853 | $473,556,552 | $473,150,542 |
| Capital Stock | $4,940,933 | $4,940,933 | $3,865,122 | $3,865,122 |
| Common Stock | $4,940,933 | $4,940,933 | $3,865,122 | $3,865,122 |
| Non Current Deferred Revenue | $24,537,215 | $33,752,720 | $50,659,474 | $75,201,277 |
| Long Term Capital Lease Obligation | $10,949,649 | $12,692,968 | $15,859,615 | $15,842,411 |
| Current Deferred Revenue | $20,130,747 | $25,165,727 | $23,591,006 | $6,469,778 |
| Current Capital Lease Obligation | $1,771,992 | $1,797,224 | $1,851,130 | $1,590,779 |
| Investments And Advances | $0 | $0 | $0 | $712,238 |
| Net PPE | $14,485,605 | $16,186,488 | $19,379,514 | $18,625,987 |
| Accumulated Depreciation | $-23,694,229 | $-20,594,103 | $-17,427,455 | $-14,765,453 |
| Gross PPE | $38,179,833 | $36,780,590 | $36,806,969 | $33,391,441 |
| Other Properties | $10,434,682 | $9,491,913 | $8,392,017 | $7,169,399 |
| Properties | $27,745,151 | $27,288,677 | $28,414,953 | $26,222,041 |
| Investmentsin Associatesat Cost | - | - | - | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | - | - |
Fetched: 2026-06-21
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-61,716,934 | $-43,366,207 | $23,141,413 | $-79,385,242 |
| Operating Activities | ||||
| Operating Cash Flow | $-60,547,075 | $-41,739,874 | $24,713,841 | $-78,573,223 |
| Cash Flow From Continuing Operating Activities | $-60,547,075 | $-41,739,874 | $24,713,841 | $-78,573,223 |
| Operating Gains Losses | $-269,526 | $-395,688 | $-1,243,262 | $-3,102,420 |
| Investing Activities | ||||
| Capital Expenditure | $-1,169,859 | $-1,626,333 | $-1,572,428 | $-812,020 |
| Investing Cash Flow | $-1,169,859 | $-4,671,407 | $4,906,525 | $-805,138 |
| Cash Flow From Continuing Investing Activities | $-1,169,859 | $-4,671,407 | $4,906,525 | $-805,138 |
| Net Other Investing Changes | - | $-3,045,074 | $-2,696,410 | - |
| Financing Activities | ||||
| Issuance Of Capital Stock | $0 | $82,159,643 | $0 | $16,196,810 |
| Financing Cash Flow | $-2,105,746 | $80,600,978 | $-2,609,244 | $-35,428,371 |
| Cash Flow From Continuing Financing Activities | $-2,105,746 | $80,600,978 | $-2,609,244 | $-35,428,371 |
| Net Common Stock Issuance | $0 | $82,159,643 | $0 | $16,196,810 |
| Common Stock Issuance | $0 | $82,159,643 | $0 | $16,196,810 |
| Other | ||||
| Repayment Of Debt | $-2,184,883 | $-1,814,428 | $-3,015,254 | $-51,664,176 |
| End Cash Position | $105,990,355 | $171,359,083 | $136,397,509 | $108,699,381 |
| Beginning Cash Position | $171,359,083 | $136,397,509 | $108,699,381 | $215,075,101 |
| Effect Of Exchange Rate Changes | $-1,546,049 | $771,877 | $687,005 | $8,431,012 |
| Changes In Cash | $-63,822,679 | $34,189,697 | $27,011,122 | $-114,806,732 |
| Proceeds From Stock Option Exercised | $79,138 | $255,763 | $406,010 | $38,995 |
| Net Issuance Payments Of Debt | $-2,184,883 | $-1,814,428 | $-3,015,254 | $-51,664,176 |
| Net Long Term Debt Issuance | $-2,184,883 | $-1,814,428 | $-3,015,254 | $-51,664,176 |
| Long Term Debt Payments | $-2,184,883 | $-1,814,428 | $-3,015,254 | $-51,664,176 |
| Net Investment Purchase And Sale | $0 | $0 | $0 | $0 |
| Sale Of Investment | $0 | $19,497,647 | $0 | $0 |
| Purchase Of Investment | $0 | $-19,497,647 | $0 | $0 |
| Net Intangibles Purchase And Sale | $0 | $0 | $9,106,548 | $0 |
| Sale Of Intangibles | $0 | $0 | $9,106,548 | $0 |
| Net PPE Purchase And Sale | $-1,169,859 | $-1,626,333 | $-1,503,613 | $-805,138 |
| Sale Of PPE | $0 | $0 | $68,815 | $6,882 |
| Purchase Of PPE | $-1,169,859 | $-1,626,333 | $-1,572,428 | $-812,020 |
| Taxes Refund Paid | $-21,791 | $225,943 | $89,460 | $-110,104 |
| Interest Received Cfo | $2,675,765 | $3,728,638 | $2,973,965 | $121,574 |
| Interest Paid Cfo | $-594,105 | $-883,129 | $-904,920 | $-4,310,127 |
| Change In Working Capital | $-19,975,913 | $-15,212,752 | $56,148,635 | $-5,724,280 |
| Change In Other Working Capital | $-19,975,913 | $-15,212,752 | $56,148,635 | $-5,724,280 |
| Other Non Cash Items | $-1,705,471 | $-3,219,406 | $-6,895,285 | $1,897,006 |
| Stock Based Compensation | $4,603,738 | $2,917,765 | $3,562,335 | $3,290,515 |
| Deferred Tax | $21,791 | $-225,943 | $-89,460 | $110,104 |
| Deferred Income Tax | $21,791 | $-225,943 | $-89,460 | $110,104 |
| Depreciation Amortization Depletion | $3,100,126 | $3,166,647 | $2,882,211 | $2,891,386 |
| Depreciation And Amortization | $3,100,126 | $3,166,647 | $2,882,211 | $2,891,386 |
| Depreciation | $3,100,126 | $3,166,647 | $2,882,211 | $2,891,386 |
| Gain Loss On Investment Securities | $-269,526 | $-395,688 | $-1,093,015 | $-3,111,595 |
| Gain Loss On Sale Of Business | $0 | $0 | $-150,247 | $0 |
| Net Income From Continuing Operations | $-48,381,690 | $-31,841,951 | $-31,809,837 | $-73,636,877 |
| Earnings Losses From Equity Investments | - | $0 | $0 | $9,175 |
| Issuance Of Debt | - | - | $0 | $0 |
| Long Term Debt Issuance | - | - | $0 | $0 |
Fetched: 2026-06-21